KREHER NERISSA 4

Accession 0001689375-23-000050

CIK 0001689375other

View on SEC.gov Company Profile

Filed

Aug 3, 8:00 PM ET

Accepted

Aug 4, 4:50 PM ET

Size

23.1 KB

Accession

0001689375-23-000050

Insider Transaction Report

Form 4

Period: 2023-08-02

Entrada Therapeutics, Inc.TRDA

KREHER NERISSA

Chief Medical Officer

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2023-08-04−6,898→ 88,012 total
Exercise: $2.10Exp: 2030-12-01→ Common Stock (6,898 underlying)
Sale
Common Stock
2023-08-02$16.01/sh−1,000$16,012→ 27,198 total
Exercise/Conversion
Common Stock
2023-08-03$2.10/sh+9,464$19,874→ 36,594 total
Sale
Common Stock
2023-08-02$15.09/sh−9,280$140,013→ 28,198 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-08-03−9,464→ 94,910 total
Exercise: $2.10Exp: 2030-12-01→ Common Stock (9,464 underlying)
Exercise/Conversion
Common Stock
2023-08-02$2.10/sh+10,348$21,731→ 37,478 total
Sale
Common Stock
2023-08-02$16.82/sh−68$1,144→ 27,130 total
Sale
Common Stock
2023-08-03$14.74/sh−9,464$139,530→ 27,130 total
Exercise/Conversion
Common Stock
2023-08-04$2.10/sh+6,898$14,486→ 34,028 total
Sale
Common Stock
2023-08-04$14.14/sh−6,898$97,521→ 27,130 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-08-02−10,348→ 104,374 total
Exercise: $2.10Exp: 2030-12-01→ Common Stock (10,348 underlying)

Footnotes (6)

[F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 to $15.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $16.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.44 to $15.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F6]25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Documents

1 file

4
wf-form4_169118219238022.xmlPrimary
FORM 4

Issuer

Entrada Therapeutics, Inc.

CIK 0001689375

→

Entity typeother

Related Parties

filerCIK 0001741850

Filing Metadata

Form type: 4
Filed: Aug 3, 8:00 PM ET
Accepted: Aug 4, 4:50 PM ET
Size: 23.1 KB

View on SEC.gov